The impact of ACE2 polymorphisms (rs1978124, rs2285666, and rs2074192) and ACE1 rs1799752 in the mortality rate of COVID-19 in different SARS-CoV-2 …

F Sheikhian, S Sadeghi Mofrad, S Tarashi… - Human Genomics, 2023 - Springer
Background Clinical severity of severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) outcomes could be influenced by genetic polymorphisms in angiotensin I-converting …

Advanced care planning during the COVID-19 pandemic: ceiling of care decisions and their implications for observational data

S Straw, M McGinlay, M Drozd, TA Slater, A Cowley… - BMC Palliative Care, 2021 - Springer
Background Observational studies investigating risk factors in coronavirus disease 2019
(COVID-19) have not considered the confounding effects of advanced care planning, such …

Drug-utilisation profiles and COVID-19

V Orlando, E Coscioni, I Guarino, S Mucherino… - Scientific Reports, 2021 - nature.com
Abstract Coronavirus disease 2019 (COVID-19) has substantially challenged healthcare
systems worldwide. By investigating population characteristics and prescribing profiles, it is …

Severe acute respiratory syndrome coronavirus 2 infection in pregnancy. A non-systematic review of clinical presentation, potential effects of physiological adaptations …

P Ayala-Ramirez, M Gonzalez, C Escudero… - Frontiers in …, 2022 - frontiersin.org
In December 2019, the novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-
CoV-2) rapidly spread to become a pandemic. To date, increasing evidence has described …

[PDF][PDF] A viewpoint on angiotensin-converting enzyme 2, anti-hypertensives and coronavirus disease 2019 (COVID-19)

SN Mali, BR Thorat, AR Chopade - Infectious Disorders-Drug …, 2021 - researchgate.net
1Department of Pharmaceutical Sciences and Technology, Institute of Chemical
Technology, Matunga, Mumbai-400019, India; 2Department of Chemistry, Government of …

Designed variants of ACE2-Fc that decouple anti-SARS-CoV-2 activities from unwanted cardiovascular effects

P Liu, X Xie, L Gao, J Jin - International Journal of Biological …, 2020 - Elsevier
Abstract Angiotensin-converting enzyme 2 (ACE2) is the entry receptor for SARS-CoV-2,
and recombinant ACE2 decoys are being evaluated as new antiviral therapies. We …

Translating bioactive peptides for COVID-19 therapy

KS Bhullar, SJ Drews, J Wu - European journal of pharmacology, 2021 - Elsevier
Abstract COVID-19 (Coronavirus disease 2019) is a global pandemic caused by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a positive-sense RNA virus. This …

Impact of treatment with renin–angiotensin system inhibitors on clinical outcomes in hypertensive patients hospitalized with COVID-19

M Negreira-Caamaño, J Piqueras-Flores… - High Blood Pressure & …, 2020 - Springer
Introduction Concerns have been raised about the possible harmfulness of angiotensin-
converter enzyme inhibitors (ACEi) and aldosterone receptor blockers (ARB) in patients with …

Currently prescribed drugs in the UK that could upregulate or downregulate ACE2 in COVID-19 disease: a systematic review

H Dambha-Miller, A Albasri, S Hodgson, CR Wilcox… - BMJ open, 2020 - bmjopen.bmj.com
Objective To review evidence on routinely prescribed drugs in the UK that could upregulate
or downregulate ACE2 and potentially affect COVID-19 disease. Design Systematic review …

Overexpression of angiotensin-converting enzyme 2 by renin-angiotensin system inhibitors. Truth or myth? A systematic review of animal studies

H Kai, M Kai, H Niiyama, N Okina, M Sasaki… - Hypertension …, 2021 - nature.com
Abstract Angiotensin-converting enzyme 2 (ACE2) protects against organ damage in
hypertension and cardiovascular diseases by counter regulating the renin-angiotensin …